C. Harbison

发表

Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.

C. Horak, T. Lynch, S. Khambata-Ford, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study.

P. Sharma, P. Ott, J. Rosenberg, 2016 .

Genetic basis for clinical response to CTLA-4 blockade in melanoma.

J. Wolchok, A. Ribas, T. Chan, 2014, The New England journal of medicine.

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

L. Crinò, J. Aerts, E. Vokes, 2015, The New England journal of medicine.

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

C. Rudin, S. Gettinger, E. Felip, 2015, The New England journal of medicine.

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

F. Cappuzzo, D. Gandara, D. Planchard, 2015, The Lancet. Oncology.

Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy

C. Horak, H. Inzunza, C. Harbison, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

David C. Smith, A. Drilon, J. Wolchok, 2019, JAMA oncology.

Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).

S. Gettinger, E. Felip, E. Vokes, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer

S. Shak, J. Baker, D. Watson, 2011, British Journal of Cancer.

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results.

S. Gettinger, N. Rizvi, H. Borghaei, 2014 .

A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts).

S. Gettinger, F. Shepherd, D. Gerber, 2013 .

Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis.

David C. Smith, L. Sequist, F. Hodi, 2014 .

Predictive markers of cetuximab efficacy in metastatic colorectal cancer

S. Khambata-Ford, C. Harbison, D. Mauro, 2008 .

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer

S. Shak, J. Baker, D. Watson, 2011, British Journal of Cancer.

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

Manuel Hidalgo, Xin Huang, Shujian Wu, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status

S. Gettinger, F. Shepherd, D. Gerber, 2014 .

Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)

David C. Smith, L. Sequist, F. Hodi, 2014 .

K-Ras mutation (mut), EGFR-related, and exploratory markers as response predictors of cetuximab in first-line advanced NSCLC: Retrospective analyses of the BMS099 trial.

C. Horak, T. Lynch, S. Khambata-Ford, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and Response With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (Pts) With Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced Non-Small Cell Lung Cancer (NSCLC)

S. Gettinger, N. Rizvi, H. Borghaei, 2014 .

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC).

S. Gettinger, F. Shepherd, D. Gerber, 2014 .

Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC.

S. Gettinger, N. Rizvi, H. Borghaei, 2014 .

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

P. Sharma, P. Ott, J. Rosenberg, 2016 .

Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): Updated results from checkmate-143.

T. Cloughesy, A. Omuro, D. Reardon, 2016 .

Biomarker Analyses in Phase 2 Single-Agent Trials of Dasatinib for Breast Cancer.

L. Ploughman, D. Brickman, C. Harbison, 2009 .

First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression.

S. Gettinger, F. Shepherd, D. Gerber, 2015 .

Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study.

P. Ascierto, P. Sharma, P. Ott, 2016 .

Abstract 2673: Association of PD-L1 combined positive score and immune gene signatures with efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients with metastatic gastroesophageal cancer (mGEC)

P. Sharma, Han Chang, N. Siemers, 2019, Clinical Research (Excluding Clinical Trials).

Analyses of PD-L1 and In ﬂ ammatory Gene Expression Association with Ef ﬁ cacy of Nivolumab (cid:1) Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer

P. Sharma, N. Siemers, P. Ott, 2021 .

Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC)

S. Gettinger, F. Shepherd, D. Gerber, 2014 .

High epiregulin (EREG) gene expression plus K-ras wild-type (WT) status as predictors of cetuximab benefit in the treatment of advanced colorectal cancer (ACRC): Results from NCIC CTG CO.17-A phase III trial of cetuximab versus best supportive care (BSC).

R. Simes, D. Tu, M. Moore, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

P. Ascierto, P. Sharma, F. D. De Braud, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

D. Jäger, P. Ascierto, P. Sharma, 2016, The Lancet. Oncology.

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

S. Gettinger, F. Shepherd, D. Gerber, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium.

R. Arceci, S. Hunger, C. Harbison, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143

K. Ligon, T. Cloughesy, A. Omuro, 2018, Neuro-oncology.

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, phase 1/2 trial

P. Sharma, F. D. De Braud, P. Ott, 2016, The Lancet. Oncology.

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

S. Gettinger, F. Shepherd, D. Gerber, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.

N. Hanna, J. Baselga, R. Herbst, 2013, European journal of cancer.

Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514.

R. Herbst, F. Shepherd, E. Felip, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC).

P. Ascierto, P. Sharma, P. Ott, 2016 .

The cetuximab experience: developing predictive biomarkers in oncology.

C. Horak, S. Khambata-Ford, C. Harbison, 2011, Personalized medicine.

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

R. Simes, D. Tu, M. Moore, 2013, British Journal of Cancer.

First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.

S. Gettinger, F. Shepherd, N. Rizvi, 2014 .

Metabolism and Disposition of [14C]BMS-690514, an ErbB/Vascular Endothelial Growth Factor Receptor Inhibitor, after Oral Administration to Humans

W. Humphreys, V. Roongta, C. Harbison, 2010, Drug Metabolism and Disposition.

Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assay.

C. Horak, E. Van Cutsem, J. Denne, 2013, Clinical colorectal cancer.

LBA18Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations

D. Schadendorf, P. Ascierto, R. Dummer, 2017 .

Checkmate 032: Nivolumab (N) alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC).

D. Jäger, P. Ascierto, P. Ott, 2016 .

Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial.

C. Horak, S. Khambata-Ford, C. Harbison, 2013, Archives of pathology & laboratory medicine.

Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer

P. Sharma, F. D. De Braud, Han Chang, 2021, Clinical Cancer Research.

674PNivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: checkmate 032

D. Jäger, P. Ascierto, P. Sharma, 2017 .

Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study.

P. Ascierto, P. Sharma, P. Ott, 2017 .

9001 ORAL A Retrospective Subgroup Analysis of EGFR Immunohistochemistry (IHC) Expression by Histo-Score Correlated to Outcomes From the BMS099 1st Line Phase III NSCLC Trial of Cetuximab (Cet) Plus Carboplatin/Taxane

T. Lynch, S. Khambata-Ford, C. Harbison, 2011 .

1229PDSMOKING HISTORY AND RESPONSE TO NIVOLUMAB IN PATIENTS WITH ADVANCED NSCLCS.

C. Sima, S. Gettinger, M. Hellmann, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)

S. Gettinger, N. Rizvi, H. Borghaei, 2014 .

3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses

S. Gettinger, F. Shepherd, D. Gerber, 2015 .

3097 Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC)

S. Gettinger, N. Rizvi, M. Hellmann, 2015 .

ATIM-16. NIVOLUMAB COMBINED WITH RADIOTHERAPY WITH OR WITHOUT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: RESULTS FROM PHASE 1 SAFETY COHORTS IN CHECKMATE 143

T. Cloughesy, N. Butowski, A. Omuro, 2016 .

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

D. Jäger, P. Ascierto, P. Sharma, 2016, The Lancet. Oncology.

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

F. Cappuzzo, D. Gandara, D. Planchard, 2015, The Lancet. Oncology.

1229PDSMOKING HISTORY AND RESPONSE TO NIVOLUMAB IN PATIENTS WITH ADVANCED NSCLCS.

C. Sima, N. Rizvi, M. Hellmann, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.